Europska Unija - hrvatski - EMA (European Medicines Agency)

ab science s.a. - masitinib mesilate - antineoplastična sredstva - psi - liječenje ne-resektabilnih pasa mast-stanica tumora (stupanj 2 ili 3) s potvrđenim mutiranim c-kit tirozin-kinaznim receptorom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ab science - masitinib mesilate - mastocitoza - antineoplastična sredstva - liječenje мастоцитоза.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ab science - masitinib mesilate - amiotrofna lateralna skleroza - antineoplastična sredstva - liječenje bočnog амиотрофического skleroze.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ab science - masitinib - neoplazme gušterače - inhibitori протеинкиназы - liječenje operirati lokalno-uobičajena ili metastaze raka gušterače .

Europska Unija - hrvatski - EMA (European Medicines Agency)

masitinib - tumori gastrointestinalnog stroma - inhibitori протеинкиназы - liječenje operirati i/ili метастатической raka стромальной tumora git (gist).

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - aksitinib - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 1 mg aksitiniba

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - aksitinib - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 5 mg aksitiniba

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

teva b.v., swensweg 5, haarlem, nizozemska - dasatinib hidrat - filmom obložena tableta - 100 mg - urbroj: jedna filmom obložena tableta sadrži 100 mg dasatiniba (u obliku hidrata)